Ruairi J Mackenzie
Senior Science Writer
Ruairi started with Technology Networks in January 2018 after completing an undergraduate degree in Neuroscience at the University of Edinburgh and a Master’s in Clinical Neuroscience from the University of Cambridge. As a senior science writer, Ruairi covers a range of scientific news and articles, with a focus on the complexities and curiosities of the brain. Ruairi also looks after search engine optimization efforts on Technology Networks and created the site’s podcast, Opinionated Science, in 2020.
Latest content from Ruairi J Mackenzie
Psilocybin Temporarily Improves Man’s Color Blindness, Report Claims
The report, published in the journal Drug Science, Policy and Law, details the experiences of a 35-year-old man who had been diagnosed with a mild case of red-green color blindness five years earlier.
VIEW
DMT Dysregulates the Brain, Study Finds
A new study has unveiled how psychedelics achieve their perception-altering effects in the human brain.
VIEW
Analytical Cannabis Digest - March 2023
This free monthly resource aims to inform you about the world of cannabis extraction, testing, and science.
VIEW
Researchers Discover New Mechanism of Psychedelic Action in the Brain
The findings could explain why the effects of psychedelics, such as neuroplasticity and even antidepressant action, vary between different drugs.
VIEW
Meet the Team Who Want To Develop Psychedelics Without the Hallucinations
Technology Networks – Analytical Cannabis’ sister publication – spoke to the team at Delix Therapeutics' to learn how their drugs can keep the benefits of psychedelics compounds while leaving behind the trip.
VIEW
Innovations in Psychedelics Research
Our latest eBook, Innovations in Psychedelics Research, a collection of features on some of the most exciting developments in psychedelics science, and exclusive interviews with some of the brilliant people making them happen.
VIEW
Psilocybin and Psychotherapy Relieve Treatment-Resistant Depression in Largest Clinical Trial to Date
The largest study to date testing the ability of the psychedelic compound psilocybin to treat a psychiatric disorder has shown that the mushroom-derived drug, delivered in combination with integrative psychotherapy sessions, significantly reduced participants’ depression as compared to a placebo after three weeks.
VIEW
Exploring How VR Could Be Used in Psychedelic-Assisted Psychotherapy
Technology Networks spoke with the two researchers who wrote a recent paper on how virtual reality might be incorporated into psychedelic-assisted psychotherapy.
VIEW
Antidepressant Psychedelics Could Be Separated From Hallucinations, Suggest Researchers
Researchers have found potentially non-hallucinatory psychedelic compounds by examining crystal structures.
VIEW
Ketamine Therapy Helps Promote Alcohol Abstinence, Trial Finds
The alcohol-use disorder trial, run by Awakn Life Sciences, has reported its first findings, and it seems like ketamine is a promising treatment.
VIEW